Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: A Prospective, Phase 4, Multicenter, Observational Study in Parkinson's Disease

NCT07219927 is registered in ClinicalTrials.gov with Supernus Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07219927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07219927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: A Prospective, Phase 4, Multicenter, Observational Study in Parkinson's Disease
Lead sponsor
Supernus Pharmaceuticals, Inc.
Phase
Observational
Overall status
Recruiting
Start date
March 31, 2025
Completion date
August 1, 2027
Enrollment
120 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease